NCT05343637View on ClinicalTrials.gov

A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

July 30, 2019

Primary Completion Date

January 17, 2020

Study Completion Date

January 17, 2020

Conditions
Pulmonary Arterial Hypertension
Interventions
COMBINATION_PRODUCT

Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)

RT234 is a drug/device combination product composed of vardenafil hydrochloride as the drug constituent and will utilize RS01 DPI device.

Trial Locations (3)

2010

St Vincent's Hospital, Darlinghurst

3004

The Alfred Hospital, Melbourne

7000

Royal Hobart Hospital, Hobart

All Listed Sponsors
lead

Respira Therapeutics, Inc.

INDUSTRY

NCT05343637 - A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension | Biotech Hunter | Biotech Hunter